Price$21.78-0.41 (-1.87%)
01:30 PM07:45 PM
News · 26 weeks72+67%
2026-04-192026-10-11
Mix1690d
- SEC Filings5(31%)
- Other5(31%)
- Analyst3(19%)
- Earnings2(13%)
- Offering1(6%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by uniQure N.V.SCHEDULE 13G/A - uniQure N.V. (0001590560) (Subject)
- PRUNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share DropThe law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. ("uniQure" or the "Company") (NASDAQ:QURE) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]What Happened?On September 29, 2026, uniQure released 48-month data for ongoing Phase I/II studies of AMT-130, the Company’s lead pipeline candidate to treat Huntington’s disease. The 48-month data revealed a smaller treatment benefit than the one the Company reported at 36 months. Specifically, AMT-130 showed a "44% slowing of disease progression
- ANALYSTuniQure downgraded by Barclays with a new price targetBarclays downgraded uniQure from Overweight to Equal Weight and set a new price target of $28.00
- SECuniQure N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - uniQure N.V. (0001590560) (Filer)
- PRuniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of disease progression (non-significant p=0.144) and TFC showed a 61% slowing of disease progression (nominal p=0.008) ~ ~ Updated data reflecting all 15 high-dose patients showed substantial treatment effect on both cUHDRS and TFC at 36 months, the timepoint that is the regulatory anchor for the submitted BLA and the confirmatory study; the new analysis demonstrated 80% slowing of disease progression based on cUHDRS (nominal p=0.005) and 67% based on TFC (nominal p=0.011) ~
- ANALYSTWilliam Blair resumed coverage on uniQureWilliam Blair resumed coverage of uniQure with a rating of Outperform
- SECuniQure N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - uniQure N.V. (0001590560) (Filer)
- PRuniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease~ Company also announces the submission of a Marketing Authorisation Application for ifezuntirgene inilparvovec in the U.K. ~ ~ Both submissions are supported by the three-year data analysis from the Phase I/II study, in which ifezuntirgene inilparvovec demonstrated a slowing of disease progression ~ LEXINGTON, Mass. and AMSTERDAM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for the accelerated approval of ifezuntirgene inilparvovec
- SECAmendment: SEC Form SCHEDULE 13G/A filed by uniQure N.V.SCHEDULE 13G/A - uniQure N.V. (0001590560) (Subject)
- SECSEC Form SCHEDULE 13G filed by uniQure N.V.SCHEDULE 13G - uniQure N.V. (0001590560) (Subject)
- ANALYSTuniQure upgraded by Wolfe Research with a new price targetWolfe Research upgraded uniQure from Peer Perform to Outperform and set a new price target of $65.00
- SECSEC Form S-8 filed by uniQure N.V.S-8 - uniQure N.V. (0001590560) (Filer)
- SECSEC Form 10-Q filed by uniQure N.V.10-Q - uniQure N.V. (0001590560) (Filer)
- SECuniQure N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - uniQure N.V. (0001590560) (Filer)
- PRuniQure Announces Second Quarter 2026 Financial Results and Provides Company Update~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~ ~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~ ~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130 and continued pipeline investment ~ ~ uniQure to host earnings call at 8:30 a.m. ET ~ LEXINGTON, Mass. and
- PRuniQure to Announce Second Quarter 2026 Financial ResultsLEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or
- SECSEC Form SCHEDULE 13G filed by uniQure N.V.SCHEDULE 13G - uniQure N.V. (0001590560) (Subject)
- INSIDERCEO, Managing Director Kapusta Matthew C exercised 21,082 units of Ordinary Shares at a strike of $19.39 and sold $952,051 worth of Ordinary Shares (21,082 units at $45.16) as part of a pre-agreed trading plan (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Medical Officer Abi-Saab Walid exercised 10,000 units of Ordinary Shares at a strike of $5.59 and sold $1,392,600 worth of Ordinary Shares (30,000 units at $46.42) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 148,235 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERDirector Kaye Jack exercised 21,167 units of Ordinary Shares at a strike of $23.44 and sold $983,030 worth of Ordinary Shares (21,167 units at $46.44) as part of a pre-agreed trading plan (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- INSIDERChief Medical Officer Abi-Saab Walid sold $67,197 worth of Ordinary Shares (1,434 units at $46.86), decreasing direct ownership by 0.85% to 168,235 units (SEC Form 4) (for withholding tax)4 - uniQure N.V. (0001590560) (Issuer)
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- INSIDERCEO, Managing Director Kapusta Matthew C exercised 32,844 units of Ordinary Shares at a strike of $31.71 and sold $1,771,174 worth of Ordinary Shares (35,412 units at $50.02) as part of a pre-agreed trading plan, decreasing direct ownership by 0.49% to 519,227 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- PRuniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesLEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were
QURE FAQ
7 questionsWhat does uniQure N.V. do?
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated...Where does QURE stock trade?
uniQure N.V. (QURE) is listed on NASDAQ.What sector and industry is QURE in?
uniQure N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did uniQure N.V. go public?
uniQure N.V. (QURE) completed its IPO in 2014.What are analysts saying about QURE?
uniQure N.V. has had 8 recent analyst actions on file. The most recent action was from Barclays: Equal Weight with a $2800.00 price target on 2026-10-05. Recent price targets range from $2800.00 to $3500.00.What companies are similar to QURE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare QURE side-by-side with any of them on Quantisnow.How can I track QURE on Quantisnow?
Quantisnow aggregates uniQure N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QURE to receive live email and push alerts on every new disclosure.